3251 related articles for article (PubMed ID: 35392977)
1. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
2. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
3. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
4. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma.
Zhu Y; Chen M; Xu D; Li TE; Zhang Z; Li JH; Wang XY; Yang X; Lu L; Jia HL; Dong QZ; Qin LX
Cell Mol Immunol; 2022 Jun; 19(6):726-737. PubMed ID: 35459855
[TBL] [Abstract][Full Text] [Related]
8. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
10. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
[TBL] [Abstract][Full Text] [Related]
11. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
12. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma.
Iwagami Y; Casulli S; Nagaoka K; Kim M; Carlson RI; Ogawa K; Lebowitz MS; Fuller S; Biswas B; Stewart S; Dong X; Ghanbari H; Wands JR
Heliyon; 2017 Sep; 3(9):e00407. PubMed ID: 28971150
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
14. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
15. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
16. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
18. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.
Tomimaru Y; Mishra S; Safran H; Charpentier KP; Martin W; De Groot AS; Gregory SH; Wands JR
Vaccine; 2015 Mar; 33(10):1256-66. PubMed ID: 25629522
[TBL] [Abstract][Full Text] [Related]
19. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
[TBL] [Abstract][Full Text] [Related]
20. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
